Cara Therapeutics | CARA - Operating Expenses


Cara Therapeutics reported $5.94M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Alterity Therapeutics Limited AUD 8.67M 893.38K Dec/2025
Cara Therapeutics USD 5.94M 983K Sep/2025
Cassava Sciences USD 11.17M 2.38M Mar/2026
Chugai Pharma JPY 162.98B 14.31B Mar/2026
Cipla INR 59.27B 1.71B Mar/2026
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 11.19M 96K Mar/2026
CSL USD 5.7B 2.82B Dec/2025
Grifols EUR 1.99B 217.4M Dec/2025
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
J&J USD 17.44B 1.53B Mar/2026
Neurocrine Biosciences USD 599.9M 22.3M Mar/2026
Pacira USD 172.75M 20.93M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
RedHill Biopharma USD 5.51M 1.08M Jun/2024
Supernus Pharmaceuticals USD 1.08B 879.06M Mar/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025